Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Hympavzi has been given a list price of $795,600 per year before discounts and rebates, which Pfizer said was in line with other prophylactic treatments for haemophilia A or B currently available ...

Pfizer Inc. (NYSE: PFE) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On July 1, GlobalNewswire reported that the Cannabis Light Market is expected to grow at a Compound ...

In another sign of the challenges facing gene therapy developers, Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable. It ...

Find the latest Pfizer Inc. (PFE) stock quote, history, news and other vital information to help you with your stock trading and investing.